FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2103787181> ?p ?o ?g. }

• W2103787181 abstract "Atherosclerotic cardiovascular disease results from complex interactions among multiple genetic and environmental factors. Thus, it is important to elucidate the influence of each factor on cholesterol metabolism. For this purpose, transgenic/gene-targeting technology is a powerful tool for studying gene functions. However, this technology has several disadvantages such as being time consuming and expensive. Accordingly, we established new animal models using in vivo gene transfer technology. In this study, we examined the feasibility of the creation of a new animal model for the study of atherosclerosis. We hypothesized that apolipoprotein (apo) E-deficient mice can be created by systemic administration of antisense apo E oligodeoxynucleotides (ODN) coupled to the HVJ-liposome complex. Initially, we examined the localization and cellular fate of FITC-labeled antisense ODN administered intravenously. FITC-labeled ODN transfection by the HVJ-liposome method resulted in fluorescence in the liver, spleen and kidney, but not in other organs such as brain. Moreover, fluorescence with the HVJ-liposome method was sustained for up to 2 weeks after transfection, which resulted in a striking difference from transfection of ODN alone or ODN in liposomes without HVJ, which showed rapid disappearance of fluorescence (within 1 day). Given these unique characteristics of the HVJ-liposome method, we next examined transfection of antisense apo E ODN by intravenous administration. Transfection of antisense apo E ODN resulted in a marked reduction of apo E mRNA levels in the liver, but no change in apo B and beta-actin mRNA levels. In mice fed a normal diet, a transient increase in cholesterol and triglyceride levels was observed in the antisense apo E-treated group, but they returned to normal levels by 6 days after transfection. Similar findings were also found in mice fed a high cholesterol diet. Neither scrambled nor mismatched ODN resulted in any increase in cholesterol. To make chronic hypercholesterolemic mice, we therefore performed repeated injections of apo E antisense ODN. Whenever antisense apo E ODN were injected, mice showed a transient increase in cholesterol and triglyceride. Cumulative administration of antisense apo E ODN resulted in a sustained increase in cholesterol for up to 3 weeks after the last transfection. Finally, mice treated with repeated injections of antisense apo E every week developed sustained hypercholesterolemia and hypertriglyceridemia until withdrawal of injections. Apolipoprotein-deficient mice created by intravenous administration of antisense ODN are a promising new animal model to help understand the role of apolipoprotein in vivo and develop a new drug therapy targeting apolipoprotein." @default.
• W2103787181 created "2016-06-24" @default.
• W2103787181 creator A5019802726 @default.
• W2103787181 creator A5025005882 @default.
• W2103787181 creator A5048654301 @default.
• W2103787181 creator A5058681981 @default.
• W2103787181 creator A5078822609 @default.
• W2103787181 creator A5091657288 @default.
• W2103787181 date "2002-11-01" @default.
• W2103787181 modified "2023-09-24" @default.
• W2103787181 title "Apolipoprotein E-deficient mice created by systemic administration of antisense oligodeoxynucleotides: a new model for lipoprotein metabolism studies" @default.
• W2103787181 cites W1590157261 @default.
• W2103787181 cites W1838520770 @default.
• W2103787181 cites W1976561922 @default.
• W2103787181 cites W1977884590 @default.
• W2103787181 cites W1988460287 @default.
• W2103787181 cites W2005431808 @default.
• W2103787181 cites W2005562002 @default.
• W2103787181 cites W2008692985 @default.
• W2103787181 cites W2013525819 @default.
• W2103787181 cites W2017319919 @default.
• W2103787181 cites W2019627348 @default.
• W2103787181 cites W2029007538 @default.
• W2103787181 cites W2032662678 @default.
• W2103787181 cites W2034968148 @default.
• W2103787181 cites W2035252462 @default.
• W2103787181 cites W2045809703 @default.
• W2103787181 cites W2048890665 @default.
• W2103787181 cites W2057471793 @default.
• W2103787181 cites W2064861744 @default.
• W2103787181 cites W2066644955 @default.
• W2103787181 cites W2067050771 @default.
• W2103787181 cites W2091460348 @default.
• W2103787181 cites W2129773029 @default.
• W2103787181 cites W2149897099 @default.
• W2103787181 cites W2156066000 @default.
• W2103787181 cites W2169074593 @default.
• W2103787181 cites W2169149496 @default.
• W2103787181 cites W2340808025 @default.
• W2103787181 doi "https://doi.org/10.1677/joe.0.1750475" @default.
• W2103787181 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12429045" @default.
• W2103787181 hasPublicationYear "2002" @default.
• W2103787181 type Work @default.
• W2103787181 sameAs 2103787181 @default.
• W2103787181 citedByCount "3" @default.
• W2103787181 crossrefType "journal-article" @default.
• W2103787181 hasAuthorship W2103787181A5019802726 @default.
• W2103787181 hasAuthorship W2103787181A5025005882 @default.
• W2103787181 hasAuthorship W2103787181A5048654301 @default.
• W2103787181 hasAuthorship W2103787181A5058681981 @default.
• W2103787181 hasAuthorship W2103787181A5078822609 @default.
• W2103787181 hasAuthorship W2103787181A5091657288 @default.
• W2103787181 hasBestOaLocation W21037871811 @default.
• W2103787181 hasConcept C102230213 @default.
• W2103787181 hasConcept C104317684 @default.
• W2103787181 hasConcept C111599444 @default.
• W2103787181 hasConcept C126322002 @default.
• W2103787181 hasConcept C134018914 @default.
• W2103787181 hasConcept C141035611 @default.
• W2103787181 hasConcept C153911025 @default.
• W2103787181 hasConcept C185154212 @default.
• W2103787181 hasConcept C185592680 @default.
• W2103787181 hasConcept C203014093 @default.
• W2103787181 hasConcept C207001950 @default.
• W2103787181 hasConcept C25938499 @default.
• W2103787181 hasConcept C2778163477 @default.
• W2103787181 hasConcept C2779134260 @default.
• W2103787181 hasConcept C2780091579 @default.
• W2103787181 hasConcept C2780931953 @default.
• W2103787181 hasConcept C54009773 @default.
• W2103787181 hasConcept C54355233 @default.
• W2103787181 hasConcept C55493867 @default.
• W2103787181 hasConcept C57089818 @default.
• W2103787181 hasConcept C62746215 @default.
• W2103787181 hasConcept C71924100 @default.
• W2103787181 hasConcept C86803240 @default.
• W2103787181 hasConcept C98274493 @default.
• W2103787181 hasConceptScore W2103787181C102230213 @default.
• W2103787181 hasConceptScore W2103787181C104317684 @default.
• W2103787181 hasConceptScore W2103787181C111599444 @default.
• W2103787181 hasConceptScore W2103787181C126322002 @default.
• W2103787181 hasConceptScore W2103787181C134018914 @default.
• W2103787181 hasConceptScore W2103787181C141035611 @default.
• W2103787181 hasConceptScore W2103787181C153911025 @default.
• W2103787181 hasConceptScore W2103787181C185154212 @default.
• W2103787181 hasConceptScore W2103787181C185592680 @default.
• W2103787181 hasConceptScore W2103787181C203014093 @default.
• W2103787181 hasConceptScore W2103787181C207001950 @default.
• W2103787181 hasConceptScore W2103787181C25938499 @default.
• W2103787181 hasConceptScore W2103787181C2778163477 @default.
• W2103787181 hasConceptScore W2103787181C2779134260 @default.
• W2103787181 hasConceptScore W2103787181C2780091579 @default.
• W2103787181 hasConceptScore W2103787181C2780931953 @default.
• W2103787181 hasConceptScore W2103787181C54009773 @default.
• W2103787181 hasConceptScore W2103787181C54355233 @default.
• W2103787181 hasConceptScore W2103787181C55493867 @default.
• W2103787181 hasConceptScore W2103787181C57089818 @default.
• W2103787181 hasConceptScore W2103787181C62746215 @default.
• W2103787181 hasConceptScore W2103787181C71924100 @default.
• W2103787181 hasConceptScore W2103787181C86803240 @default.

• next